Arzerra FDA Approval History
FDA Approved: Yes (First approved October 26, 2009)
Brand name: Arzerra
Generic name: ofatumumab
Dosage form: Injection
Treatment for: Chronic Lymphocytic Leukemia
Arzerra (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia.
Development timeline for Arzerra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.